Viatris formed with merger of Upjohn and Mylan
US pharmaceutical companies Upjohn (a division of Pfizer) and Mylan have merged to form a company called Viatris, nearly 16 months after the move was first announced.
The new company will immediately become a major player in the generics market, with estimated global sales of over $19 billion, compared to $127billion for current market leader, Teva.
Viatris’ product portfolio includes legacy Pfizer products such as Viagra and Lipitor, as well as Mylan’s Epipen.
The merger received EU approval in April 2020, although the deal was conditional on Mylan divesting certain generic medicines sold by Mylan in 20 European countries to meet competition concerns.
Viatris is headquartered in the US, and has global centres in Pittsburgh, Shanghai, and Hyderabad, India. Its portfolio comprises more than 1,400 approved molecules across a wide range of therapeutic areas that it will sell across 165 countries and territories.
The company is immediately embarking on a “significant global restructuring programme in order to achieve synergies of $1 billion and ensure the new company is optimally structured and efficiently resourced”.
Understand how fungal nail infections develop and help manage customer expectations around treatment
Upgrade your contraceptive consultations by exploring the interactive pack to learn about a daily oral contraceptive pill
Record my learning outcomes
Inspiring stories related to health, fitness and the pursuit of wellbeing
More like this
Numark video hails pharmacy successes during Covid-19
Numark has produced a short film depicting their member pharmacies' successes during the pandemic.
1 Min Article
EPB chair slams government plan to lift free prescription age to 66
The English Pharmacy Board chair Thorrun Govind has warned the move will lead to greater health inequalities
2 Min Article